



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## CLL MRD Flow Panel

### Alternative Name

CLL Minimal Residual Disease Panel

### Methodology

Flow Cytometry

### Test Description

Available as global test only. Markers are CD3, CD5, CD19, CD20, CD22, CD43, CD79b, CD81 (8 markers).

### Clinical Significance

Monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) has become increasingly important as treatments improve. This flow cytometry panel follows the strategy developed by the European Research Initiative in CLL (ERIC) and can detect MRD at the 0.01% level. Detection of MRD above 0.01% is reported to be an independent predictor of progression-free survival and overall survival in CLL patients treated with chemoimmunotherapy. The prognostic value of achieving MRD-negative status with other CLL therapies is under investigation in clinical trials.

### Specimen Requirements

- **Bone marrow aspirate:** 2-3 mL EDTA preferred. Sodium heparin is acceptable.
- **Peripheral blood:** 5-6 mL EDTA preferred. Sodium heparin is acceptable.
- **NY Clients:** Please provide Date and Time of Collection.
- **Note:** Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.

### Storage & Transportation

**Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. Note: New York State samples must be received within 48 hours from collection per NYS requirements.** Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

88184(x1), 88185(x7). Add 88187(x1) for global.

### New York Approved

Yes

### Level of Service

Global

### Turnaround Time

24 hours

## References

1. Rawstron AC, Fazi A, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for MRD detection in CLL: an European Research Initiative on CLL study. *Leukemia*. 2016;30:929-936.
2. Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow residual disease monitoring in CLL. *Leukemia*. 2013;27:142-149.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 050324